Tozorakimab

托雷奇单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NameTozorakimab
Drug Alias NameIL-33 mAb (MedImmune)Interleukin 33 monoclonal antibody (MedImmune)MEDI-3506
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-33 inhibitors
TargetsInterleukin-33
Therapy Area/IndicationsDermatitis, AtopicDiabetic NephropathiesPulmonary Disease, Chronic Obstructive +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbMedimmune Pharma Bv +[6] 
Inactive CompaniesMedimmune Llc
Active IndicationsDermatitis, AtopicDiabetic NephropathiesPulmonary Disease, Chronic Obstructive +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG